Open session of the standing technical committee of the EUFMD- 2004

Appendix 1 Research group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease Closed Session, 11 October 2004 Provisional Agenda Original Paper ref. 1 2

Opening of the Session and Adoption of the Agenda Papers for adoption - post-Gerzensee working groups 2.1 Biosecurity working group

Haas/SanchezViscaino

2a

Paper for adoption: Minimum requirements for FMD serology laboratories 2.2 Diagnostic reagent bank ii. For adoption: EUFMD Position paper

Bernd Haas

2b

2.3 Sample transport 2.3.1 For adoption: Guidelines paper

Vilmos Palfi

2c

i.

3

Progress reports- post-Gerzensee working groups 3.1 Assisted delivery of samples from third countries 3.2 Vaccine selection for the European banks 3.2.1 3.2.2

Related issues - the OIE ad hoc group on vaccine and antigen banks Global FMD mapping/modelling surveillance for circulating strains

3.3 Comparative evaluation of candidate DIVA tests 3.3.1 Findings and recommendations of the Improcon/EUFMD/EC Brescia workshop 3.4 Post-vaccination surveillance 3.4.1 Gerzensee issues: within herd prevalence estimates, NSP test performance 3.4.2

Secrt.

Kris de Clercq

Matthias Greiner

Paton/De Clercq/Dekker David Paton

3h

3.6 Proficiency panel for virus detection; progress report (pilot study) 3.7 Pen-side tests –evaluation/guidelines on use

David Paton

3i

3.9 Virus inactivation kinetics 3.10 Laboratory sero-diagnostic capacity 3.11 Bio-security working group Short report of EUFMD/EC supported studies relating to validation of DIVA tests 4.1 Prevalence in vaccinated herds exposed to infection – Israel 4.2 Collection of sera/specimens for DIVA test validation – SAT viruses 5

David Paton

New EC Directive: is compliance with PVS requirements technically feasible? 3.5 FAO Phase XVIII progress and plan

3.8 Laboratory contingency planning

4

Secrt.

Items arising from the Executive Committee 69th and 70th Sessions 5.1 Performance of new oil adjuvanted vaccine and conventional vaccines produced by the SAP Institute in 2004 5.2 Guidelines for monitoring performance of vaccines and vaccination in the field

Open session of the standing technical committee of the EUFMD- 2004

Articles inside

Appendix 82

Appendix 77

Appendix 78

Appendix 79

Appendix 81

Appendix 80

Appendix 76

Appendix 75

Appendix 64

Appendix 72

Appendix 73

Appendix 65

Appendix 67

Appendix 63

Appendix 62

Appendix 54

Appendix 61

Appendix 55

Appendix 59

Appendix 60

Appendix 56

Appendix 42

Appendix 52

Appendix 50

Appendix 46

Appendix 37

Appendix 38

Appendix 41

Appendix 40

Appendix 36

Appendix 35

Appendix 34

Appendix 28

Appendix 31

Appendix 29

Appendix 33

Appendix 27

Appendix 26

Appendix 25

Appendix 23

Appendix 22

Appendix 15

Appendix 16

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

Appendix 19

Appendix 14

Appendix 13

Appendix 5

Appendix 12

Appendix 3

Appendix 4

Appendix 8

Appendix 2

Open Session

Closed Session

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

Item 14 – Regulatory compliance

Item 10 – International issues

Item 9 – Novel vaccines

Item 7 – Optimisation of conventional vaccines

Item 4 – Managing diagnostic demands

Item 8 – Regulatory issues affecting FMD vacine selection and use

Item 3 – Transmission and its control

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

Item 1 – Recent findings in molecular epidemiology of FMDV

Item 2 – Surveillance: for what purpose and how much is enough?

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection